These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16123676)

  • 21. Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.
    Huigen MC; van Ham PM; de Graaf L; Kagan RM; Boucher CA; Nijhuis M
    Retrovirology; 2008 Feb; 5():20. PubMed ID: 18271957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
    Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
    Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.
    Stürmer M; Staszewski S; Doerr HW; Larder B; Bloor S; Hertogs K
    Antimicrob Agents Chemother; 2003 Jan; 47(1):54-61. PubMed ID: 12499169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
    de Ronde A; van Dooren M; van Der Hoek L; Bouwhuis D; de Rooij E; van Gemen B; de Boer R; Goudsmit J
    J Virol; 2001 Jan; 75(2):595-602. PubMed ID: 11134272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
    Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
    Miller MD; Margot NA; Lamy PD; Fuller MD; Anton KE; Mulato AS; Cherrington JM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):450-8. PubMed ID: 11511821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
    Garcia-Lerma JG; Nidtha S; Blumoff K; Weinstock H; Heneine W
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13907-12. PubMed ID: 11698656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
    Paintsil E; Margolis A; Collins JA; Alexander L
    J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.
    Masquelier B; Chaix ML; Burgard M; Lechenadec J; Doussin A; Simon F; Cottalorda J; Izopet J; Tamalet C; Douard D; Fleury H; Mayaux MJ; Blanche S; Rouzioux C;
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):99-104. PubMed ID: 11404530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.
    Diallo K; Oliveira M; Moisi D; Brenner B; Wainberg MA; Götte M
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2254-6. PubMed ID: 12069983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
    Goudsmit J; Weverling GJ; van der Hoek L; de Ronde A; Miedema F; Coutinho RA; Lange JM; Boerlijst MC
    AIDS; 2001 Nov; 15(17):2293-301. PubMed ID: 11698703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.
    Imamichi T; Berg SC; Imamichi H; Lopez JC; Metcalf JA; Falloon J; Lane HC
    J Virol; 2000 Dec; 74(23):10958-64. PubMed ID: 11069990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
    Lengruber RB; Delviks-Frankenberry KA; Nikolenko GN; Baumann J; Santos AF; Pathak VK; Soares MA
    J Antimicrob Chemother; 2011 Apr; 66(4):702-8. PubMed ID: 21393163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.
    Magierowska-Jung M; Agut H; Katlama C; Autran B; Huraux JM
    J Med Virol; 1997 Jan; 51(1):48-55. PubMed ID: 8986949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.
    Stilianakis NI; Boucher CA; De Jong MD; Van Leeuwen R; Schuurman R; De Boer RJ
    J Virol; 1997 Jan; 71(1):161-8. PubMed ID: 8985335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.